UK-based MeiraGTx Holdings plc (Nasdaq: MGTX) announced a USD 100 million underwritten public offering of ordinary shares, with proceeds directed toward extending its operating runway through potential commercial launches of two late-stage gene therapy candidates. The UK-headquartered company stated that net proceeds, combined with existing cash, are expected to fund operating expenses and capital expenditure requirements into the second half of 2028, contingent on regulatory approvals for its lead assets.
The offering comprised 11,111,111 ordinary shares priced at USD 9.00 per share, with all shares sold directly by MeiraGTx. No warrants were issued as part of this transaction. The offering was structured as an underwritten deal pursuant to an effective shelf registration statement on Form S-3, originally filed with the SEC on December 21, 2023 and declared effective December 29, 2023. BofA Securities and Goldman Sachs & Co. LLC acted as joint book-running managers, with Raymond James serving as co-manager. The offering was expected to close on or about April 17, 2026, subject to customary closing conditions. No specific institutional end-buyers were disclosed, as is standard for underwritten public offerings of this structure. No company insider participation was referenced in the offering documentation.
Company overview and pipeline